Expertise in
29
conditions

Dr. Marwan N. Sabbagh

Neurology
240 W Thomas Rd, Ste 301, 
Phoenix, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Referral required
Before you request
Expertise in
29
conditions
240 W Thomas Rd, Ste 301, 
Phoenix, AZ 

Overview

Marwan Sabbagh is a Neurologist practicing medicine in Phoenix, Arizona.

Dr. Sabbagh is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Alzheimer's Disease, Dementia, Lewy Body Dementia (LBD), Movement Disorders, and Deep Brain Stimulation.

Dr. Sabbagh is board certified in Psychiatry & Neurology (Neurology). He is actively involved in clinical research, co-authoring 308 peer reviewed articles and participating in 14 clinical trials. Dr. Sabbagh is currently accepting new patients.

Specialties

Neurology

Licenses

Psychiatry & Neurology in CA

Board Certifications

Psychiatry & Neurology (Neurology)

Fellowships

San Diego Veterans Affairs Medical Center

Hospital Affiliations

St Josephs Hospital And Medical Center
Chandler Regional Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
PacificSource
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Barrow MAMDC and Barrow Cognitive
240 W Thomas Rd, Ste 301, Phoenix, AZ 85013

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Alzheimer's Clinical Trial Consortium for Down Syndrome (ACTC-DS) Trial-Ready Cohort - Down Syndrome (TRC-DS)
Alzheimer's Clinical Trial Consortium for Down Syndrome (ACTC-DS) Trial-Ready Cohort - Down Syndrome (TRC-DS)
Enrollment Status: Recruiting
Publish Date: May 18, 2026
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Enrollment Status: Completed
Publish Date: August 21, 2026
Intervention Type: Drug
Study Drug: Solanezumab
Study Phase: Phase 3
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: March 19, 2026
Intervention Type: Drug
Study Drug: LY3002813
Study Phase: Phase 2
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Enrollment Status: Completed
Publish Date: March 11, 2026
Escitalopram for Agitation in Alzheimer's Disease
Escitalopram for Agitation in Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Escitalopram
Study Phase: Phase 3
Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD)
Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD)
Enrollment Status: Completed
Publish Date: November 20, 2024
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Enrollment Status: Completed
Publish Date: June 27, 2024
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
Therapeutic Effects of Exercise in Adults With Amnestic Mild Cognitive Impairment (MCI)
Therapeutic Effects of Exercise in Adults With Amnestic Mild Cognitive Impairment (MCI)
Enrollment Status: Completed
Publish Date: February 15, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
View 9 Less Clinical Trials

308 Total Publications

Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes.
Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes.
Journal: Drugs
Published: July 21, 2026
Similar Doctors
Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Neurosurgical Associates LTD.

2910 N 3rd Ave, 
Phoenix, AZ 
 (0.1 miles away)
602-406-3181
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ashutosh Jadhav is a Neurologist practicing medicine in Phoenix, Arizona. Dr. Jadhav is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Stroke, Subarachnoid Hemorrhage, Brain Aneurysm, Thrombectomy, and Stent Placement.

Expertise in
16
conditions
Expertise in
16
conditions
Referral required
Before you request

Muhammad Ali Parkinson Center

240 West Thomas Road, Suite 301, 
Phoenix, AZ 
 (0.1 miles away)
602-406-6262
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

My mission, along with the Dignity Health Medical Group, is to focus on innovative clinical care and the pursuit of excellence through scholarly activities. This allows me to provide patients with state-of-the-art patient services and exceptional patient experiences. Dr. Shill is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Parkinson's Disease, Essential Tremor, Movement Disorders, Deep Brain Stimulation, and Tissue Biopsy. Dr. Shill is board certified in Psychiatry & Neurology (Neurology). Dr. Shill is currently accepting new patients.

Expertise in
17
conditions
Dr. Angus A. Wilfong
Neurology | Pediatrics | Pediatric Neurology
Expertise in
17
conditions
Dr. Angus A. Wilfong
Neurology | Pediatrics | Pediatric Neurology
Referral may be required
Before you request

PCH Neurology

1919 E Thomas Rd, Ambulatory Bldg 3rd Fl, 
Phoenix, AZ 
 (2.2 miles away)
602-933-0970
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Angus Wilfong is a Neurologist and a Pediatrics provider practicing medicine in Phoenix, Arizona. Dr. Wilfong is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Hypothalamic Hamartomas, Status Epilepticus, Epilepsy, and Seizures. Dr. Wilfong is board certified in Psychiatry & Neurology CSQ In Child Neurology, Psychiatry & Neurology (Sub: Epilepsy), and Psychiatry & Neurology (Sub: Clinical Neurophysiolog. Dr. Wilfong is currently accepting new patients.

Frequently Asked Questions about Dr. Marwan N. Sabbagh

How do I make an appointment with Dr. Marwan N. Sabbagh?

You can book an appointment with Dr. Marwan N. Sabbagh by calling their office at 602-406-6262. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Marwan N. Sabbagh a top-rated expert for Alzheimer's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Marwan N. Sabbagh is classified as an Elite expert for Alzheimer's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Marwan N. Sabbagh specialize in?

While Dr. Marwan N. Sabbagh is a Neurology, they have specific expertise in Alzheimer's Disease, Dementia, and Lewy Body Dementia (LBD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Marwan N. Sabbagh participate in research or clinical trials?

Yes. Dr. Marwan N. Sabbagh has published 308 articles and abstracts on conditions like Alzheimer's Disease. You can view a list of Dr. Marwan N. Sabbagh's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Marwan N. Sabbagh accept my insurance?

Dr. Marwan N. Sabbagh accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 602-406-6262 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sabbagh's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 19 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile